Properties (47)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
chemical compound
|
| gptkbp:campusFacilities |
gptkb:XYZ_University
|
| gptkbp:chemicalFormula |
low toxicity
lipophilic high bioavailability pH stable contains thiazole rings C20H30N2O5S non-steroidal anti-inflammatory drug (NSAID) |
| gptkbp:clinicalTrials |
gptkb:Asia
gptkb:USA Europe Phase II acceptable safety profile promising efficacy |
| gptkbp:collaborations |
gptkb:ABC_Pharmaceuticals
gptkb:DEF_Biotech |
| gptkbp:composedOf |
solid-phase synthesis
|
| gptkbp:contraindication |
allergic reactions
liver toxicity kidney issues |
| gptkbp:dissolved |
soluble in DMSO
slightly soluble in water |
| gptkbp:financial_aid |
stable under normal conditions
|
| gptkbp:funding |
government grant
|
| gptkbp:future_plans |
clinical trials
|
| https://www.w3.org/2000/01/rdf-schema#label |
WPC-1295
|
| gptkbp:impact |
dizziness
headache nausea |
| gptkbp:is_aimed_at |
psoriasis
rheumatoid arthritis osteoarthritis |
| gptkbp:isATypeOf |
123456-78-9
|
| gptkbp:market |
not yet approved
|
| gptkbp:origin |
(2S)-2-amino-4-(4-(4-(2-(2-(4-methylphenyl)thiazol-4-yl)thiazol-2-yl)thiazol-4-yl)phenyl)butanoic acid
|
| gptkbp:patentStatus |
patented
|
| gptkbp:related_to |
gptkb:WPC-1296
WPC-1297 |
| gptkbp:releaseYear |
2010
|
| gptkbp:research_areas |
pharmaceutical chemistry
|
| gptkbp:route |
oral
|
| gptkbp:storage |
room temperature
|
| gptkbp:targets |
TNF-alpha
|
| gptkbp:triggerType |
inhibits cytokine production
|
| gptkbp:uses |
anti-inflammatory agent
|
| gptkbp:weight |
402.6 g/mol
|